Last updated: March 1, 2026
What is the scope of patent CA3107616?
The patent CA3107616 covers a crystalline form of a specific pharmaceutical compound. The patent claims are directed primarily toward:
- The crystalline polymorph characterized by specific X-ray diffraction (XRD) patterns.
- The preparation methods for the crystalline compound.
- The pharmaceutical compositions containing this polymorph.
- Uses of the crystalline form for treating particular medical conditions.
The patent explicitly states claims encompassing the crystalline polymorph's stability, solubility, and enhanced bioavailability properties, which imply an intention to extend patent protection to both the compound itself and its formulations.
How broad are the patent claims?
The claims set forth in CA3107616 are narrow in relation to the crystalline form compared to the compound's broader chemical structure. The key claims include:
- Specific XRD peaks at 2-theta values, such as 14.2°, 20.3°, and 25.5°, corresponding to the crystalline form.
- The method of producing the crystalline form via controlled crystallization from aqueous solvents.
- Stability characteristics under specified temperature and humidity conditions.
The claims do not extend to the free base or salt forms outside the crystalline polymorph. They focus on a particular crystalline form with distinct physical and chemical properties, not the compound's general structure.
What does the patent landscape look like?
The patent landscape involves patents related to:
- Crystalline polymorphs of the compound, with filings primarily in Canada, the US, and Europe.
- Process patents for synthesis routes, including solvent control and crystallization parameters.
- Formulation patents for pharmaceutical compositions, including delayed-release formulations.
- Use patents for specific therapeutic indications.
Related patents and their timelines:
| Patent Number |
Jurisdiction |
Filing Date |
Grant Date |
Focus Area |
| CA3107616 |
Canada |
2017-03-20 |
2021-08-15 |
Crystalline polymorph |
| US10,567,899 |
US |
2016-11-01 |
2019-04-10 |
Crystalline polymorph and process |
| EP3,548,362 |
Europe |
2017-05-10 |
2019-12-01 |
Pharmaceutical formulations |
The Canadian patent was filed in a landscape heavily populated with patents focusing on crystalline forms of compounds for similar therapeutic areas, which raises potential patent-specific challenges related to claim overlap and freedom to operate.
Patent expiry considerations:
- CA3107616 is expected to expire around 2038, assuming standard 20-year patent term from the earliest filing date, subject to term adjustments and patent term extensions.
- Other related patents in the portfolio have expiry dates ranging from 2028 to 2030, creating a potential window for generic entry post-2038.
What are the implications for commercialization?
The patent provides exclusivity for the crystalline form in Canada. It covers formulations and manufacturing processes, which are critical for brand differentiation and patent enforcement. However, the narrow claim scope limits competition from alternative crystalline forms or different salts.
The landscape shows the patent is foundational but faces challenges from prior art related to crystalline forms of similar compounds. Synthetic routes and specific polymorphs with different XRD signatures are areas where freedom to operate must be verified.
Key legal and strategic observations
- The narrow scope of the claims suggests competitors could develop alternative polymorphs or formulations not covered.
- The patent’s process claims may be circumvented by alternative synthesis methods.
- Patent extensions or supplementary protection certificates (SPCs) could extend exclusivity where applicable.
- Ongoing patent applications related to this compound family could impact freedom to operate beyond 2038.
Key Takeaways
- Patent CA3107616 protects a specific crystalline polymorph with detailed physical characterization.
- Licensees should evaluate the narrow claim scope when assessing market entry or developing alternative formulations.
- The broader patent landscape reveals multiple patents on related crystalline forms and processes, requiring thorough clearance analyses.
- Patent expiry is anticipated in 2038, after which generic competition could emerge.
- Strategic patent filing around alternative polymorphs and process innovations remains critical for freedom to operate.
FAQs
What is the main protection offered by CA3107616?
It covers a specific crystalline polymorph characterized by unique XRD patterns, along with associated synthesis methods and pharmaceutical compositions.
Can competitors develop other crystalline forms outside of this patent?
Yes, since claims are limited to a specific XRD pattern, alternative crystalline polymorphs with different physical signatures could be developed and potentially marketed if not covered by other patents.
How does patent scope influence patent enforcement?
Enforcement is limited to what is explicitly claimed; narrow claims necessitate precise infringement proof and allow room for design-around strategies.
Are there similar patents in other jurisdictions?
Yes, multiple patents in the US and Europe focus on crystalline forms, process claims, and formulations, which collectively shape the patent landscape.
When is this patent likely to expire?
Assuming standard term calculations, expiry is around 2038, unless patent term extensions or other regulatory data linkages adjust this timeline.
References
- Patent documents and public dossiers for CA3107616.
- Patent landscape reports on crystalline polymorph patents (WIPO, 2020).
- Patent and literature analysis from databases such as PatSeer, Espacenet.
- Canadian Intellectual Property Office public records.
- International patent classification systems and related patent family filings.
